NCT03852303 (OAETREATe) is a Phase 4 clinical trial of ivermectin in Epilepsy, sponsored by Universiteit Antwerpen.

Who is sponsoring NCT03852303?

NCT03852303 is sponsored by Universiteit Antwerpen.

What drugs are being tested in NCT03852303?

Interventions in NCT03852303: ivermectin.

Is NCT03852303 still recruiting?

NCT03852303 is currently completed. Last updated 26 September 2019.

Last reviewed 2019-09-26 · How we verify

NCT03852303: OAETREATe

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Ivermectin Treatment of Persons With Onchocerciasis-associated Epilepsy

Completed Phase 4 Last updated 26 September 2019

What this trial tests

Phase 4 trial testing ivermectin in Epilepsy in 197 participants. Completed in 1 July 2019.

Timeline

1 October 2017

Primary endpoint
31 March 2019

1 July 2019

Quick facts

Lead sponsor	Universiteit Antwerpen
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	treatment
Enrollment	197
Start date	1 October 2017
Primary completion	31 March 2019
Estimated completion	1 July 2019
Sites	1 location across Democratic Republic of the Congo

Drugs / interventions tested

ivermectin (ivermectin) — full drug profile →

Conditions studied

Epilepsy — all drugs for Epilepsy →

Sponsor

Universiteit Antwerpen — full company profile →

Who can join

5 and older, any sex, with Epilepsy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Randomized clinical trial in the Logo health zone, in Ituri province, Democratic Republic of Congo to compare seizure freedom in onchocerciasis infested epilepsy patients who ivermectin treatment once a year compared to 2 and 3 times a year. All participants also receive anti-epileptic drugs according to local guidelines for epilepsy treatment. Participants will be followed for 12 months. The primary endpoint is seizure freedom defined as no seizures during the last fourth months of the trial.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Epileptic seizures.
Anwar H, Khan QU, Nadeem N, Pervaiz I, et al · · 2020 · cited 83× · PMID 32577498 · DOI 10.15190/d.2020.7
Single Versus Multiple Dose Ivermectin Regimen in Onchocerciasis-infected Persons with Epilepsy Treated with Phenobarbital: A Randomized Clinical Trial in the Democratic Republic of Congo
Mandro M, Dusambimana A, Siewe Fodjo JN, Mukendi D, et al · · 2020 · DOI 10.20944/preprints202001.0259.v1

Verify or expand the search:

Other trials of ivermectin

Trials testing the same drug.

NCT05180461 — Emodepside Phase II Trial for Treatment of Onchocerciasis · Phase 2 · active not recruiting
NCT04275999 — Rosacea and Ivermectin · Phase 2 · completed
NCT04746365 — Ivermectin Role in Covid-19 Clinical Trial · Phase 4 · completed

Other recruiting trials for Epilepsy

Currently open trials in the same condition.

NCT07095933 — The Safety and Efficacy Evaluation of Everolimus as an Adjunctive Treatment for Focal Refractory Epilepsy · EARLY_PHASE1 · recruiting
NCT07224191 — Hippocampal Oscillations During Exploration · NA · recruiting
NCT07219407 — A Long-term Study of the Safety and Effectiveness of RAP-219 in Adults With Focal Onset Seizures · Phase 2 · recruiting
NCT07417280 — LIFUS For Neurological Disorders · NA · recruiting
NCT07490769 — Levetiracetam Three Times Daily in Epilepsy · Phase 3 · recruiting

Other Universiteit Antwerpen trials

Trials by the same sponsor.

NCT07407569 — Developing a First-void Urine-based Infection Model to Study HPV-specific Antibody-virion Interaction Before and After H · Phase 2 · recruiting
NCT07355101 — Personalized Exercise Coaching to Improve Quality of Life in Pediatric IBD · NA · active not recruiting
NCT06962579 — The Effect of Personalized Exercise Interventions for the Prevention of Chemotherapy-induced Peripheral Neuropathy · NA · recruiting
NCT06999473 — Assessment and Treat Neglect Patients With a VR Application · NA · not yet recruiting
NCT07161531 — Test-retest Reliability of sEMG to Measure Fatigue in Adolescents · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03852303 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Universiteit Antwerpen
Last refreshed: 26 September 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03852303.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing